<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">36550205</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>07</Day></DateCompleted><DateRevised><Year>2023</Year><Month>06</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1348-4214</ISSN><JournalIssue CitedMedium="Internet"><Volume>46</Volume><Issue>3</Issue><PubDate><Year>2023</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Hypertension research : official journal of the Japanese Society of Hypertension</Title><ISOAbbreviation>Hypertens Res</ISOAbbreviation></Journal><ArticleTitle>COVID-19 pandemic and hypertension: an updated report from the Japanese Society of Hypertension project team on COVID-19.</ArticleTitle><Pagination><StartPage>589</StartPage><EndPage>600</EndPage><MedlinePgn>589-600</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41440-022-01134-5</ELocationID><Abstract><AbstractText>The number of reported cases with coronavirus disease 2019 (COVID-19) has exceeded 620 million worldwide, still having a profound impact on people's health and daily lives since its occurrence and outbreak in December 2019. From the early phase of the COVID-19 pandemic, there has been a concern that the rapid spread of this communicable disease can negatively influence non-communicable diseases. Accumulating data indicate that the restriction on the access to medical care, psychological distress, and life-style changes triggered by the pandemic have indeed affected blood pressure control in hypertensive patients. Since our previous report in 2020 that summarized the findings of the literature related to COVID-19 and hypertension, there has been a considerable progress in our understanding of the association between these two disorders; nonetheless, there are remaining challenges and emerging questions in the field. In this article, we aim to summarize the latest information on the impact of the pandemic on blood pressure control, the use of the renin-angiotensin system inhibitors in patients with COVID-19, and the blood pressure changes as one of the possible post-acute sequelae of COVID-19 (also known as long COVID). We also summarize the evidence of telemedicine and COVID-19 vaccination in hypertensive subjects, based on data available as of June 2022.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s), under exclusive licence to The Japanese Society of Hypertension.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shibata</LastName><ForeName>Shigeru</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Nephrology, Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan. shigeru.shibata@med.teikyo-u.ac.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kobayashi</LastName><ForeName>Kazuo</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Kobayashi Internal Medicine Clinic, Sagamihara, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tanaka</LastName><ForeName>Masami</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Adachi Medical Center, Tokyo Women's Medical University, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Asayama</LastName><ForeName>Kei</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Hygiene and Public Health, Teikyo University School of Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yamamoto</LastName><ForeName>Eiichiro</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Kumamoto University Graduate School of Medical Sciences, Kumamoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakagami</LastName><ForeName>Hironori</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Health Development and Medicine, Graduate School of Medicine, Osaka University, Osaka, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Infectious Disease Education and Research, Osaka University, Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoshide</LastName><ForeName>Satoshi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University School of Medicine, Tochigi, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kishi</LastName><ForeName>Takuya</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Graduate School of Medicine (Cardiology), International University of Health and Welfare, Okawa, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matsumoto</LastName><ForeName>Chisa</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Preventive Medicine, Tokyo Medical University, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mogi</LastName><ForeName>Masaki</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, Ehime University Graduate School of Medicine, Ehime, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morimoto</LastName><ForeName>Satoshi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Endocrinology and Hypertension, Tokyo Women's Medical University, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yamamoto</LastName><ForeName>Koichi</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Geriatric and General Medicine, Graduate School of Medicine, Osaka University, Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mukoyama</LastName><ForeName>Masashi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Nephrology, Kumamoto University Graduate School of Medical Sciences, Kumamoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kario</LastName><ForeName>Kazuomi</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University School of Medicine, Tochigi, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Node</LastName><ForeName>Koichi</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Saga University, Saga, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rakugi</LastName><ForeName>Hiromi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Geriatric and General Medicine, Graduate School of Medicine, Osaka University, Osaka, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Hypertens Res</MedlineTA><NlmUniqueID>9307690</NlmUniqueID><ISSNLinking>0916-9636</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Hypertens Res. 2023 May;46(5):1353-1354. doi: 10.1038/s41440-023-01207-z</RefSource><PMID Version="1">36843117</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006973" MajorTopicYN="Y">Hypertension</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012084" MajorTopicYN="N">Renin-Angiotensin System</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">High blood pressure</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">NCD</Keyword><Keyword MajorTopicYN="N">RAS inhibitors</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword></KeywordList><CoiStatement>The Department of Health Development and Medicine in Osaka University is an endowed department supported by Anges, Daicel, and FunPep.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>9</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>12</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>11</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>12</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>12</Month><Day>22</Day><Hour>23</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>12</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36550205</ArticleId><ArticleId IdType="pmc">PMC9780104</ArticleId><ArticleId IdType="doi">10.1038/s41440-022-01134-5</ArticleId><ArticleId IdType="pii">10.1038/s41440-022-01134-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Shibata S, Arima H, Asayama K, Hoshide S, Ichihara A, Ishimitsu T, et al. Hypertension and related diseases in the era of COVID-19: a report from the Japanese Society of Hypertension Task Force on COVID-19. Hypertens Res. 2020;43:1028&#x2013;46. doi: 10.1038/s41440-020-0515-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41440-020-0515-0</ArticleId><ArticleId IdType="pmc">PMC7393334</ArticleId><ArticleId IdType="pubmed">32737423</ArticleId></ArticleIdList></Reference><Reference><Citation>Itoh H. A new normal for hypertension medicine with coronavirus disease-2019 (COVID-19): proposal from the president of the Japanese Society of Hypertension. Hypertens Res. 2020;43:857&#x2013;8. doi: 10.1038/s41440-020-0497-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41440-020-0497-y</ArticleId><ArticleId IdType="pmc">PMC7301354</ArticleId><ArticleId IdType="pubmed">32555413</ArticleId></ArticleIdList></Reference><Reference><Citation>Lauring AS, Tenforde MW, Chappell JD, Gaglani M, Ginde AA, McNeal T, et al. Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study. BMJ. 2022;376:e069761. doi: 10.1136/bmj-2021-069761.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2021-069761</ArticleId><ArticleId IdType="pmc">PMC8905308</ArticleId><ArticleId IdType="pubmed">35264324</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsumoto C, Shibata S, Kishi T, Morimoto S, Mogi M, Yamamoto Y, et al. Long COVID and Hypertension-Related Disorders: A Report from the Japanese Society of Hypertension Project Team on COVID-19. Hypertens Res. in press.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9793823</ArticleId><ArticleId IdType="pubmed">36575228</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeuchi I. COVID-19 first stage in Japan&#x2014;how we treat &#x2018;Diamond Princess Cruise Ship&#x2019; with 3700 passengers? Acute Med Surg. 2020;7:e506. doi: 10.1002/ams2.506.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ams2.506</ArticleId><ArticleId IdType="pmc">PMC7161807</ArticleId><ArticleId IdType="pubmed">32313661</ArticleId></ArticleIdList></Reference><Reference><Citation>Skeete J, Connell K, Ordunez P, DiPette DJ. Approaches to the management of hypertension in resource-limited settings: strategies to overcome the hypertension crisis in the post-COVID era. Integr Blood Press Control. 2020;13:125&#x2013;33. doi: 10.2147/IBPC.S261031.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/IBPC.S261031</ArticleId><ArticleId IdType="pmc">PMC7532072</ArticleId><ArticleId IdType="pubmed">33061561</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamaguchi S, Okada A, Sunaga S, Ikeda Kurakawa K, Yamauchi T, Nangaku M, et al. Impact of COVID-19 pandemic on healthcare service use for non-COVID-19 patients in Japan: retrospective cohort study. BMJ Open. 2022;12:e060390. doi: 10.1136/bmjopen-2021-060390.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2021-060390</ArticleId><ArticleId IdType="pmc">PMC9058318</ArticleId><ArticleId IdType="pubmed">35466081</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks SK, Webster RK, Smith LE, Woodland L, Wessely S, Greenberg N, et al. The psychological impact of quarantine and how to reduce it: rapid review of the evidence. Lancet. 2020;395:912&#x2013;20. doi: 10.1016/S0140-6736(20)30460-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30460-8</ArticleId><ArticleId IdType="pmc">PMC7158942</ArticleId><ArticleId IdType="pubmed">32112714</ArticleId></ArticleIdList></Reference><Reference><Citation>Talevi D, Socci V, Carai M, Carnaghi G, Faleri S, Trebbi E, et al. Mental health outcomes of the CoVID-19 pandemic. Riv Psichiatr. 2020;55:137&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">32489190</ArticleId></ArticleIdList></Reference><Reference><Citation>Vindegaard N, Benros ME. COVID-19 pandemic and mental health consequences: systematic review of the current evidence. Brain Behav Immun. 2020;89:531&#x2013;42. doi: 10.1016/j.bbi.2020.05.048.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2020.05.048</ArticleId><ArticleId IdType="pmc">PMC7260522</ArticleId><ArticleId IdType="pubmed">32485289</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong M, Zheng J. Letter to the editor: Headline stress disorder caused by Netnews during the outbreak of COVID-19. Health Expect. 2020;23:259&#x2013;60. doi: 10.1111/hex.13055.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/hex.13055</ArticleId><ArticleId IdType="pmc">PMC7104635</ArticleId><ArticleId IdType="pubmed">32227627</ArticleId></ArticleIdList></Reference><Reference><Citation>Bagus P, Pena-Ramos JA, Sanchez-Bayon A. COVID-19 and the political economy of mass hysteria. Int J Environ Res Public Health. 2021;18:1376. doi: 10.3390/ijerph18041376.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph18041376</ArticleId><ArticleId IdType="pmc">PMC7913136</ArticleId><ArticleId IdType="pubmed">33546144</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323:1239&#x2013;42. doi: 10.1001/jama.2020.2648.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.2648</ArticleId><ArticleId IdType="pubmed">32091533</ArticleId></ArticleIdList></Reference><Reference><Citation>Faulkner J, O&#x2019;Brien WJ, McGrane B, Wadsworth D, Batten J, Askew CD, et al. Physical activity, mental health and well-being of adults during initial COVID-19 containment strategies: a multi-country cross-sectional analysis. J Sci Med Sport. 2021;24:320&#x2013;6. doi: 10.1016/j.jsams.2020.11.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsams.2020.11.016</ArticleId><ArticleId IdType="pmc">PMC7711171</ArticleId><ArticleId IdType="pubmed">33341382</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson E, Boyland E, Chisholm A, Harrold J, Maloney NG, Marty L, et al. Obesity, eating behavior and physical activity during COVID-19 lockdown: a study of UK adults. Appetite. 2021;156:104853. doi: 10.1016/j.appet.2020.104853.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.appet.2020.104853</ArticleId><ArticleId IdType="pmc">PMC7540284</ArticleId><ArticleId IdType="pubmed">33038479</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Sidor A, Rzymski P, Pivari F, Soldati L, Attina A, Cinelli G, et al. Dietary choices and habits during COVID-19 lockdown: experience from Poland. Nutrients. 2020;12:1657. doi: 10.3390/nu12061657.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu12061657</ArticleId><ArticleId IdType="pmc">PMC7352682</ArticleId><ArticleId IdType="pubmed">32503173</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez-de-Quel O, Suarez-Iglesias D, Lopez-Flores M, Perez CA. Physical activity, dietary habits and sleep quality before and during COVID-19 lockdown: a longitudinal study. Appetite. 2021;158:105019. doi: 10.1016/j.appet.2020.105019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.appet.2020.105019</ArticleId><ArticleId IdType="pmc">PMC8580211</ArticleId><ArticleId IdType="pubmed">33161046</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding D, Cheng M, Del Pozo Cruz B, Lin T, Sun S, Zhang L, et al. How COVID-19 lockdown and reopening affected daily steps: evidence based on 164,630 person-days of prospectively collected data from Shanghai, China. Int J Behav Nutr Phys Act. 2021;18:40. doi: 10.1186/s12966-021-01106-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12966-021-01106-x</ArticleId><ArticleId IdType="pmc">PMC7968558</ArticleId><ArticleId IdType="pubmed">33731132</ArticleId></ArticleIdList></Reference><Reference><Citation>Barcin-Guzeldere HK, Devrim-Lanpir A. The association between body mass index, emotional eating and perceived stress during COVID-19 partial quarantine in healthy adults. Public Health Nutr. 2022;25:43&#x2013;50. doi: 10.1017/S1368980021002974.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S1368980021002974</ArticleId><ArticleId IdType="pmc">PMC8365042</ArticleId><ArticleId IdType="pubmed">34261563</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancello R, Soranna D, Zambra G, Soldati A, Zambon A, Invitti C, et al. Determinants of the lifestyle changes during COVID-19 pandemic in the residents of northern Italy. Int J Environ Res Public Health. 2020;17:6287. doi: 10.3390/ijerph17176287.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph17176287</ArticleId><ArticleId IdType="pmc">PMC7504331</ArticleId><ArticleId IdType="pubmed">32872336</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Renzo L, Gualtieri P, Pivari F, Soldati L, Attina A, Cinelli G, et al. Eating habits and lifestyle changes during COVID-19 lockdown: an Italian survey. J Transl Med. 2020;18:229. doi: 10.1186/s12967-020-02399-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-020-02399-5</ArticleId><ArticleId IdType="pmc">PMC7278251</ArticleId><ArticleId IdType="pubmed">32513197</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobayashi K, Chin K, Umezawa S, Ito S, Yamamoto H, Nakano S, et al. Influence of stress induced by the first announced state of emergency due to coronavirus disease 2019 on outpatient blood pressure management in Japan. Hypertens Res. 2022;45:675&#x2013;85. doi: 10.1038/s41440-021-00832-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41440-021-00832-w</ArticleId><ArticleId IdType="pmc">PMC8705072</ArticleId><ArticleId IdType="pubmed">34952950</ArticleId></ArticleIdList></Reference><Reference><Citation>Satoh M, Murakami T, Obara T, Metoki H. Time-series analysis of blood pressure changes after the guideline update in 2019 and the coronavirus disease pandemic in 2020 using Japanese longitudinal data. Hypertens Res. 2022;45:1408&#x2013;17. doi: 10.1038/s41440-022-00961-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41440-022-00961-w</ArticleId><ArticleId IdType="pmc">PMC9206892</ArticleId><ArticleId IdType="pubmed">35718828</ArticleId></ArticleIdList></Reference><Reference><Citation>Endo K, Miki T, Itoh T, Kubo H, Ito R, Ohno K, et al. Impact of the COVID-19 pandemic on glycemic control and blood pressure control in patients with diabetes in Japan. Intern Med. 2022;61:37&#x2013;48. doi: 10.2169/internalmedicine.8041-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.2169/internalmedicine.8041-21</ArticleId><ArticleId IdType="pmc">PMC8810256</ArticleId><ArticleId IdType="pubmed">34980759</ArticleId></ArticleIdList></Reference><Reference><Citation>Laffin LJ, Kaufman HW, Chen Z, Niles JK, Arellano AR, Bare LA, et al. Rise in blood pressure observed among US adults during the COVID-19 pandemic. Circulation. 2022;145:235&#x2013;7. doi: 10.1161/CIRCULATIONAHA.121.057075.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.121.057075</ArticleId><ArticleId IdType="pmc">PMC8763044</ArticleId><ArticleId IdType="pubmed">34865499</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah NP, Clare RM, Chiswell K, Navar AM, Shah BR, Peterson ED. Trends of blood pressure control in the U.S. during the COVID-19 pandemic. Am Heart J. 2022;247:15&#x2013;23. doi: 10.1016/j.ahj.2021.11.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ahj.2021.11.017</ArticleId><ArticleId IdType="pmc">PMC8662834</ArticleId><ArticleId IdType="pubmed">34902314</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W, Zhang S, Deng Y, Wu S, Ren J, Sun G, et al. Trial of intensive blood-pressure control in older patients with hypertension. N Engl J Med. 2021;385:1268&#x2013;79. doi: 10.1056/NEJMoa2111437.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2111437</ArticleId><ArticleId IdType="pubmed">34491661</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang S, Zhong Y, Wang L, Yin X, Li Y, Liu Y, et al. Anxiety, home blood pressure monitoring, and cardiovascular events among older hypertension patients during the COVID-19 pandemic. Hypertens Res. 2022;45:856&#x2013;65. doi: 10.1038/s41440-022-00852-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41440-022-00852-0</ArticleId><ArticleId IdType="pmc">PMC8778505</ArticleId><ArticleId IdType="pubmed">35064249</ArticleId></ArticleIdList></Reference><Reference><Citation>Iaccarino G, Grassi G, Borghi C, Ferri C, Salvetti M, Volpe M, et al. Age and multimorbidity predict death among COVID-19 patients: results of the SARS-RAS Study of the Italian Society of Hypertension. Hypertension. 2020;76:366&#x2013;72. doi: 10.1161/HYPERTENSIONAHA.120.15324.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.120.15324</ArticleId><ArticleId IdType="pubmed">32564693</ArticleId></ArticleIdList></Reference><Reference><Citation>McFarlane E, Linschoten M, Asselbergs FW, Lacy PS, Jedrzejewski D, Williams B, et al. The impact of pre-existing hypertension and its treatment on outcomes in patients admitted to hospital with COVID-19. Hypertens Res. 2022;45:834&#x2013;45. doi: 10.1038/s41440-022-00893-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41440-022-00893-5</ArticleId><ArticleId IdType="pmc">PMC8963889</ArticleId><ArticleId IdType="pubmed">35352027</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang B, Li R, Lu Z, Huang Y. Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis. Aging. 2020;12:6049&#x2013;57. doi: 10.18632/aging.103000.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/aging.103000</ArticleId><ArticleId IdType="pmc">PMC7185114</ArticleId><ArticleId IdType="pubmed">32267833</ArticleId></ArticleIdList></Reference><Reference><Citation>Ran J, Song Y, Zhuang Z, Han L, Zhao S, Cao P, et al. Blood pressure control and adverse outcomes of COVID-19 infection in patients with concomitant hypertension in Wuhan, China. Hypertens Res. 2020;43:1267&#x2013;76. doi: 10.1038/s41440-020-00541-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41440-020-00541-w</ArticleId><ArticleId IdType="pmc">PMC7450040</ArticleId><ArticleId IdType="pubmed">32855527</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamazaki O, Shibata S. Severe COVID-19 and preexisting hypertension: a matter of age? Hypertens Res. 2022;45:1523&#x2013;5. doi: 10.1038/s41440-022-00978-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41440-022-00978-1</ArticleId><ArticleId IdType="pmc">PMC9283815</ArticleId><ArticleId IdType="pubmed">35840751</ArticleId></ArticleIdList></Reference><Reference><Citation>Menni C, Valdes AM, Freidin MB, Sudre CH, Nguyen LH, Drew DA, et al. Real-time tracking of self-reported symptoms to predict potential COVID-19. Nat Med. 2020;26:1037&#x2013;40. doi: 10.1038/s41591-020-0916-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0916-2</ArticleId><ArticleId IdType="pmc">PMC7751267</ArticleId><ArticleId IdType="pubmed">32393804</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudre CH, Murray B, Varsavsky T, Graham MS, Penfold RS, Bowyer RC, et al. Attributes and predictors of long COVID. Nat Med. 2021;27:626&#x2013;31. doi: 10.1038/s41591-021-01292-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01292-y</ArticleId><ArticleId IdType="pmc">PMC7611399</ArticleId><ArticleId IdType="pubmed">33692530</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y, Yuan D, Chen DG, Ng RH, Wang K, Choi J, et al. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell. 2022;185:881&#x2013;95.e820. doi: 10.1016/j.cell.2022.01.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.01.014</ArticleId><ArticleId IdType="pmc">PMC8786632</ArticleId><ArticleId IdType="pubmed">35216672</ArticleId></ArticleIdList></Reference><Reference><Citation>Tleyjeh IM, Saddik B, AlSwaidan N, AlAnazi A, Ramakrishnan RK, Alhazmi D, et al. Prevalence and predictors of Post-Acute COVID-19 Syndrome (PACS) after hospital discharge: a cohort study with 4 months median follow-up. PLoS ONE. 2021;16:e0260568. doi: 10.1371/journal.pone.0260568.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0260568</ArticleId><ArticleId IdType="pmc">PMC8651136</ArticleId><ArticleId IdType="pubmed">34874962</ArticleId></ArticleIdList></Reference><Reference><Citation>Blomberg B, Mohn KG, Brokstad KA, Zhou F, Linchausen DW, Hansen BA, et al. Long COVID in a prospective cohort of home-isolated patients. Nat Med. 2021;27:1607&#x2013;13. doi: 10.1038/s41591-021-01433-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01433-3</ArticleId><ArticleId IdType="pmc">PMC8440190</ArticleId><ArticleId IdType="pubmed">34163090</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y, Xu E, Bowe B, Al-Aly Z. Long-term cardiovascular outcomes of COVID-19. Nat Med. 2022;28:583&#x2013;90. doi: 10.1038/s41591-022-01689-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01689-3</ArticleId><ArticleId IdType="pmc">PMC8938267</ArticleId><ArticleId IdType="pubmed">35132265</ArticleId></ArticleIdList></Reference><Reference><Citation>Saeed S, Tadic M, Larsen TH, Grassi G, Mancia G. Coronavirus disease 2019 and cardiovascular complications: focused clinical review. J Hypertens. 2021;39:1282&#x2013;92. doi: 10.1097/HJH.0000000000002819.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/HJH.0000000000002819</ArticleId><ArticleId IdType="pmc">PMC9904438</ArticleId><ArticleId IdType="pubmed">33687179</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. Nature. 2021;594:259&#x2013;64. doi: 10.1038/s41586-021-03553-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03553-9</ArticleId><ArticleId IdType="pubmed">33887749</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen K, Ren S, Heath K, Dasmari&#xf1;as MC, Jubilo KG, Guo Y, et al. Risk of persistent and new clinical sequelae among adults aged 65 years and older during the post-acute phase of SARS-CoV-2 infection: retrospective cohort study. BMJ. 2022;376:e068414. doi: 10.1136/bmj-2021-068414.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2021-068414</ArticleId><ArticleId IdType="pmc">PMC8828141</ArticleId><ArticleId IdType="pubmed">35140117</ArticleId></ArticleIdList></Reference><Reference><Citation>Daugherty SE, Guo Y, Heath K, Dasmarinas MC, Jubilo KG, Samranvedhya J, et al. Risk of clinical sequelae after the acute phase of SARS-CoV-2 infection: retrospective cohort study. BMJ. 2021;373:n1098. doi: 10.1136/bmj.n1098.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n1098</ArticleId><ArticleId IdType="pmc">PMC8132065</ArticleId><ArticleId IdType="pubmed">34011492</ArticleId></ArticleIdList></Reference><Reference><Citation>Hultstrom M, von Seth M, Frithiof R. Hyperreninemia and low total body water may contribute to acute kidney injury in COVID-19 patients in intensive care. J Hypertens. 2020;38:1613&#x2013;4. doi: 10.1097/HJH.0000000000002531.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/HJH.0000000000002531</ArticleId><ArticleId IdType="pmc">PMC7282406</ArticleId><ArticleId IdType="pubmed">32472780</ArticleId></ArticleIdList></Reference><Reference><Citation>de Abajo FJ, Rodriguez-Martin S, Lerma V, Mejia-Abril G, Aguilar M, Garcia-Luque A, et al. Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study. Lancet. 2020;395:1705&#x2013;14. doi: 10.1016/S0140-6736(20)31030-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)31030-8</ArticleId><ArticleId IdType="pmc">PMC7255214</ArticleId><ArticleId IdType="pubmed">32416785</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, Wang X, Chen J, Zhang H, Deng A. Association of renin-angiotensin system inhibitors with severity or risk of death in patients with hypertension hospitalized for coronavirus disease 2019 (COVID-19) infection in Wuhan, China. JAMA Cardiol. 2020;5:825&#x2013;30. doi: 10.1001/jamacardio.2020.1624.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamacardio.2020.1624</ArticleId><ArticleId IdType="pmc">PMC7180726</ArticleId><ArticleId IdType="pubmed">32324209</ArticleId></ArticleIdList></Reference><Reference><Citation>Mancia G, Rea F, Ludergnani M, Apolone G, Corrao G. Renin-angiotensin-aldosterone system blockers and the risk of COVID-19. N Engl J Med. 2020;382:2431&#x2013;40. doi: 10.1056/NEJMoa2006923.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2006923</ArticleId><ArticleId IdType="pmc">PMC7206933</ArticleId><ArticleId IdType="pubmed">32356627</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynolds HR, Adhikari S, Pulgarin C, Troxel AB, Iturrate E, Johnson SB, et al. Renin-angiotensin-aldosterone system inhibitors and risk of COVID-19. N Engl J Med. 2020;382:2441&#x2013;8. doi: 10.1056/NEJMoa2008975.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2008975</ArticleId><ArticleId IdType="pmc">PMC7206932</ArticleId><ArticleId IdType="pubmed">32356628</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang G, Tan Z, Zhou L, Yang M, Peng L, Liu J, et al. Effects of ARBs and ACEIs on virus infection, inflammatory status and clinical outcomes in COVID-19 patients with hypertension: a single center retrospective study. Hypertension. 2020;76:51&#x2013;8. doi: 10.1161/HYPERTENSIONAHA.120.15143.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.120.15143</ArticleId><ArticleId IdType="pubmed">32348166</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang P, Zhu L, Cai J, Lei F, Qin JJ, Xie J, et al. Association of inpatient use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19. Circ Res. 2020;126:1671&#x2013;81. doi: 10.1161/CIRCRESAHA.120.317134.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.120.317134</ArticleId><ArticleId IdType="pmc">PMC7265882</ArticleId><ArticleId IdType="pubmed">32302265</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasan SS, Kow CS, Hadi MA, Zaidi STR, Merchant HA. Mortality and disease severity among COVID-19 patients receiving renin-angiotensin system inhibitors: a systematic review and meta-analysis. Am J Cardiovasc Drugs. 2020;20:571&#x2013;90. doi: 10.1007/s40256-020-00439-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40256-020-00439-5</ArticleId><ArticleId IdType="pmc">PMC7486167</ArticleId><ArticleId IdType="pubmed">32918209</ArticleId></ArticleIdList></Reference><Reference><Citation>Kerneis M, Ferrante A, Guedeney P, Vicaut E, Montalescot G. Severe acute respiratory syndrome coronavirus 2 and renin-angiotensin system blockers: a review and pooled analysis. Arch Cardiovasc Dis. 2020;113:797&#x2013;810. doi: 10.1016/j.acvd.2020.09.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.acvd.2020.09.002</ArticleId><ArticleId IdType="pmc">PMC7580526</ArticleId><ArticleId IdType="pubmed">33199208</ArticleId></ArticleIdList></Reference><Reference><Citation>Koshy AN, Murphy AC, Farouque O, Ramchand J, Burrell LM, Yudi MB. Renin-angiotensin system inhibition and risk of infection and mortality in COVID-19: a systematic review and meta-analysis. Intern Med J. 2020;50:1468&#x2013;74. doi: 10.1111/imj.15002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imj.15002</ArticleId><ArticleId IdType="pmc">PMC7753674</ArticleId><ArticleId IdType="pubmed">33191600</ArticleId></ArticleIdList></Reference><Reference><Citation>Patoulias D, Katsimardou A, Stavropoulos K, Imprialos K, Kalogirou MS, Doumas M. Renin-angiotensin system inhibitors and COVID-19: a systematic review and meta-analysis. Evidence for significant geographical disparities. Curr Hypertens Rep. 2020;22:90. doi: 10.1007/s11906-020-01101-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11906-020-01101-w</ArticleId><ArticleId IdType="pmc">PMC7481766</ArticleId><ArticleId IdType="pubmed">32910274</ArticleId></ArticleIdList></Reference><Reference><Citation>Pranata R, Permana H, Huang I, Lim MA, Soetedjo NNM, Supriyadi R, et al. The use of renin angiotensin system inhibitor on mortality in patients with coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis. Diabetes Metab Syndr. 2020;14:983&#x2013;90. doi: 10.1016/j.dsx.2020.06.047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dsx.2020.06.047</ArticleId><ArticleId IdType="pmc">PMC7319940</ArticleId><ArticleId IdType="pubmed">32615377</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuzawa Y, Ogawa H, Kimura K, Konishi M, Kirigaya J, Fukui K, et al. Renin-angiotensin system inhibitors and the severity of coronavirus disease 2019 in Kanagawa, Japan: a retrospective cohort study. Hypertens Res. 2020;43:1257&#x2013;66. doi: 10.1038/s41440-020-00535-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41440-020-00535-8</ArticleId><ArticleId IdType="pubmed">32820236</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsunaga N, Hayakawa K, Terada M, Ohtsu H, Asai Y, Tsuzuki S, et al. Clinical epidemiology of hospitalized patients with coronavirus disease 2019 (COVID-19) in Japan: report of the COVID-19 registry Japan. Clin Infect Dis. 2021;73:e3677&#x2013;89. doi: 10.1093/cid/ciaa1470.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa1470</ArticleId><ArticleId IdType="pmc">PMC7543311</ArticleId><ArticleId IdType="pubmed">32986793</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshihara F, Ohtsu H, Nakai M, Tsuzuki S, Hayakawa K, Terada M, et al. Renin-angiotensin system blocker and the COVID-19 aggravation in patients with hypertension, diabetes, renal failure, cerebro-cardiovascular disease, or pulmonary disease: report by the COVID-19 registry Japan. J Cardiol. 2022;80:292&#x2013;7. doi: 10.1016/j.jjcc.2022.04.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jjcc.2022.04.001</ArticleId><ArticleId IdType="pmc">PMC8989871</ArticleId><ArticleId IdType="pubmed">35469713</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee MMY, Docherty KF, Sattar N, Mehta N, Kalra A, Nowacki AS, et al. Renin-angiotensin system blockers, risk of SARS-CoV-2 infection and outcomes from CoViD-19: systematic review and meta-analysis. Eur Heart J Cardiovasc Pharmacother. 2022;8:165&#x2013;78. doi: 10.1093/ehjcvp/pvaa138.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ehjcvp/pvaa138</ArticleId><ArticleId IdType="pmc">PMC7799280</ArticleId><ArticleId IdType="pubmed">33337478</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Q, Tang S, Li Y. The divergent protective effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on clinical outcomes of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis. Ann Palliat Med. 2022;11:1253&#x2013;63. doi: 10.21037/apm-21-972.</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/apm-21-972</ArticleId><ArticleId IdType="pubmed">34775774</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopes RD, Macedo AVS, de Barros ESPGM, Moll-Bernardes RJ, Dos Santos TM, Mazza L, et al. Effect of discontinuing vs continuing angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on days alive and out of the hospital in patients admitted with COVID-19: a randomized clinical trial. JAMA. 2021;325:254&#x2013;64. doi: 10.1001/jama.2020.25864.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.25864</ArticleId><ArticleId IdType="pmc">PMC7816106</ArticleId><ArticleId IdType="pubmed">33464336</ArticleId></ArticleIdList></Reference><Reference><Citation>Macedo AVS, de Barros ESPGM, de Paula TC, Moll-Bernardes RJ, Mendonca Dos Santos T, Mazza L, et al. Discontinuing vs continuing ACEIs and ARBs in hospitalized patients with COVID-19 according to disease severity: insights from the BRACE CORONA trial. Am Heart J. 2022;249:86&#x2013;97. doi: 10.1016/j.ahj.2022.04.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ahj.2022.04.001</ArticleId><ArticleId IdType="pmc">PMC8993458</ArticleId><ArticleId IdType="pubmed">35405099</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen JB, Hanff TC, William P, Sweitzer N, Rosado-Santander NR, Medina C, et al. Continuation versus discontinuation of renin-angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial. Lancet Respir Med. 2021;9:275&#x2013;84. doi: 10.1016/S2213-2600(20)30558-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(20)30558-0</ArticleId><ArticleId IdType="pmc">PMC7832152</ArticleId><ArticleId IdType="pubmed">33422263</ArticleId></ArticleIdList></Reference><Reference><Citation>Bauer A, Schreinlechner M, Sappler N, Dolejsi T, Tilg H, Aulinger BA, et al. Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open-label trial. Lancet Respir Med. 2021;9:863&#x2013;72. doi: 10.1016/S2213-2600(21)00214-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(21)00214-9</ArticleId><ArticleId IdType="pmc">PMC8195495</ArticleId><ArticleId IdType="pubmed">34126053</ArticleId></ArticleIdList></Reference><Reference><Citation>Kai H, Kai M, Niiyama H, Okina N, Sasaki M, Maeda T, et al. Overexpression of angiotensin-converting enzyme 2 by renin-angiotensin system inhibitors. Truth or myth? A systematic review of animal studies. Hypertens Res. 2021;44:955&#x2013;68. doi: 10.1038/s41440-021-00641-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41440-021-00641-1</ArticleId><ArticleId IdType="pmc">PMC7943405</ArticleId><ArticleId IdType="pubmed">33750913</ArticleId></ArticleIdList></Reference><Reference><Citation>International Society of Hypertension. A statement from the International Society of Hypertension on COVID-19. https://ish-world.com/a-statement-from-the-international-society-of-hypertension-on-covid-19/</Citation></Reference><Reference><Citation>European Society of Hypertension. Statement of the European Society of Hypertension (ESH) on hypertension, renin-angiotensin system (RAS) blockers and COVID-19. https://www.eshonline.org/esh-content/uploads/2020/06/Statement-ESH-on-Hypertension-RAS-Blockers-and-COVID-19-Update-April-15-2020.pdf</Citation></Reference><Reference><Citation>ESC Council on Hypertension. Position statement of the ESC Council on hypertension on ACE-inhibitors and angiotensin receptor blockers. https://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/News/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang</Citation></Reference><Reference><Citation>Statement from the American Heart Association. Patients taking ACE-i and ARBs who contract COVID-19 should continue treatment, unless otherwise advised by their physician. https://newsroom.heart.org/news/patients-taking-ace-i-and-arbs-who-contract-covid-19-should-continue-treatment-unless-otherwise-advised-by-their-physician</Citation></Reference><Reference><Citation>Japanese Society of Hypertension. Information of COVID-19. https://www.jpnsh.jp/corona.html</Citation></Reference><Reference><Citation>Keech C, Albert G, Cho I, Robertson A, Reed P, Neal S, et al. Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. N Engl J Med. 2020;383:2320&#x2013;32. doi: 10.1056/NEJMoa2026920.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2026920</ArticleId><ArticleId IdType="pmc">PMC7494251</ArticleId><ArticleId IdType="pubmed">32877576</ArticleId></ArticleIdList></Reference><Reference><Citation>Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397:99&#x2013;111. doi: 10.1016/S0140-6736(20)32661-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32661-1</ArticleId><ArticleId IdType="pmc">PMC7723445</ArticleId><ArticleId IdType="pubmed">33306989</ArticleId></ArticleIdList></Reference><Reference><Citation>Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med. 2020;383:2603&#x2013;15. doi: 10.1056/NEJMoa2034577.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2034577</ArticleId><ArticleId IdType="pmc">PMC7745181</ArticleId><ArticleId IdType="pubmed">33301246</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson EJ, Rouphael NG, Widge AT, Jackson LA, Roberts PC, Makhene M, et al. Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults. N Engl J Med. 2020;383:2427&#x2013;38. doi: 10.1056/NEJMoa2028436.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2028436</ArticleId><ArticleId IdType="pmc">PMC7556339</ArticleId><ArticleId IdType="pubmed">32991794</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamashita K, Suzuki A, Takebayashi S, Toguchi A, Ogitani K, Niizeki N, et al. Differential dynamics of humoral and cell-mediated immunity with three doses of BNT162b2 SARS-CoV-2 vaccine in healthcare workers in Japan: a prospective cohort study. Vaccines. 2022;10:1050.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9323262</ArticleId><ArticleId IdType="pubmed">35891213</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujigaki H, Yamamoto Y, Koseki T, Banno S, Ando T, Ito H, et al. Antibody responses to BNT162b2 vaccination in Japan: monitoring vaccine efficacy by measuring IgG antibodies against the receptor-binding domain of SARS-CoV-2. Microbiol Spectr. 2022;10:e0118121. doi: 10.1128/spectrum.01181-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/spectrum.01181-21</ArticleId><ArticleId IdType="pmc">PMC8768797</ArticleId><ArticleId IdType="pubmed">35044205</ArticleId></ArticleIdList></Reference><Reference><Citation>Lustig Y, Sapir E, Regev-Yochay G, Cohen C, Fluss R, Olmer L, et al. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers. Lancet Respir Med. 2021;9:999&#x2013;1009. doi: 10.1016/S2213-2600(21)00220-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(21)00220-4</ArticleId><ArticleId IdType="pmc">PMC8253545</ArticleId><ArticleId IdType="pubmed">34224675</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe M, Balena A, Tuccinardi D, Tozzi R, Risi R, Masi D, et al. Central obesity, smoking habit, and hypertension are associated with lower antibody titres in response to COVID-19 mRNA vaccine. Diabetes Metab Res Rev. 2022;38:e3465. doi: 10.1002/dmrr.3465.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/dmrr.3465</ArticleId><ArticleId IdType="pmc">PMC8209952</ArticleId><ArticleId IdType="pubmed">33955644</ArticleId></ArticleIdList></Reference><Reference><Citation>Parthymou A, Habeos EE, Habeos GI, Deligakis A, Livieratos E, Marangos M, et al. Factors associated with anti-SARS-CoV-2 antibody titres 3 months post-vaccination with the second dose of BNT162b2 vaccine: a longitudinal observational cohort study in western Greece. BMJ Open. 2022;12:e057084. doi: 10.1136/bmjopen-2021-057084.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2021-057084</ArticleId><ArticleId IdType="pmc">PMC9121112</ArticleId><ArticleId IdType="pubmed">35589363</ArticleId></ArticleIdList></Reference><Reference><Citation>Sourij C, Tripolt NJ, Aziz F, Aberer F, Forstner P, Obermayer AM, et al. Humoral immune response to COVID-19 vaccination in diabetes is age-dependent but independent of type of diabetes and glycaemic control: the prospective COVAC-DM cohort study. Diabetes Obes Metab. 2022;24:849&#x2013;58. doi: 10.1111/dom.14643.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dom.14643</ArticleId><ArticleId IdType="pmc">PMC9303917</ArticleId><ArticleId IdType="pubmed">34984802</ArticleId></ArticleIdList></Reference><Reference><Citation>Papadokostaki E, Tentolouris A, Anastasiou IA, Psichogiou M, Iliaki E, Eleftheriadou I, et al. Immunogenicity of SARS-CoV-2 BNT162b2 vaccine in people with diabetes: a prospective observational study. Vaccines. 2022;10:382. doi: 10.3390/vaccines10030382.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10030382</ArticleId><ArticleId IdType="pmc">PMC8954340</ArticleId><ArticleId IdType="pubmed">35335014</ArticleId></ArticleIdList></Reference><Reference><Citation>Terpos E, Trougakos IP, Karalis V, Ntanasis-Stathopoulos I, Gumeni S, Apostolakou F, et al. Kinetics of anti-SARS-CoV-2 antibody responses 3 months post complete vaccination with BNT162b2; a prospective study in 283 health workers. Cells. 2021;10:1942. doi: 10.3390/cells10081942.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10081942</ArticleId><ArticleId IdType="pmc">PMC8394923</ArticleId><ArticleId IdType="pubmed">34440710</ArticleId></ArticleIdList></Reference><Reference><Citation>Meylan S, Livio F, Foerster M, Genoud PJ, Marguet F, Wuerzner G, et al. Stage III hypertension in patients after mRNA-based SARS-CoV-2 vaccination. Hypertension. 2021;77:e56&#x2013;7. doi: 10.1161/HYPERTENSIONAHA.121.17316.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.121.17316</ArticleId><ArticleId IdType="pmc">PMC8115421</ArticleId><ArticleId IdType="pubmed">33764160</ArticleId></ArticleIdList></Reference><Reference><Citation>Zappa M, Verdecchia P, Spanevello A, Visca D, Angeli F. Blood pressure increase after Pfizer/BioNTech SARS-CoV-2 vaccine. Eur J Intern Med. 2021;90:111&#x2013;3. doi: 10.1016/j.ejim.2021.06.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejim.2021.06.013</ArticleId><ArticleId IdType="pmc">PMC8206586</ArticleId><ArticleId IdType="pubmed">34158234</ArticleId></ArticleIdList></Reference><Reference><Citation>Komine-Aizawa S, Haruyama Y, Deguchi M, Hayakawa S, Kawana K, Kobashi G, et al. The vaccination status and adverse effects of COVID-19 vaccine among pregnant women in Japan in 2021. J Obstet Gynaecol Res. 2022;48:1561&#x2013;9. doi: 10.1111/jog.15285.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jog.15285</ArticleId><ArticleId IdType="pmc">PMC9347631</ArticleId><ArticleId IdType="pubmed">35537777</ArticleId></ArticleIdList></Reference><Reference><Citation>Bozkurt B, Kamat I, Hotez PJ. Myocarditis with COVID-19 mRNA vaccines. Circulation. 2021;144:471&#x2013;84. doi: 10.1161/CIRCULATIONAHA.121.056135.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.121.056135</ArticleId><ArticleId IdType="pmc">PMC8340726</ArticleId><ArticleId IdType="pubmed">34281357</ArticleId></ArticleIdList></Reference><Reference><Citation>Mevorach D, Anis E, Cedar N, Bromberg M, Haas EJ, Nadir E, et al. Myocarditis after BNT162b2 mRNA vaccine against Covid-19 in Israel. N Engl J Med. 2021;385:2140&#x2013;9. doi: 10.1056/NEJMoa2109730.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2109730</ArticleId><ArticleId IdType="pmc">PMC8531987</ArticleId><ArticleId IdType="pubmed">34614328</ArticleId></ArticleIdList></Reference><Reference><Citation>Oster ME, Shay DK, Su JR, Gee J, Creech CB, Broder KR, et al. Myocarditis cases reported after mRNA-based COVID-19 vaccination in the US from December 2020 to August 2021. JAMA. 2022;327:331&#x2013;40. doi: 10.1001/jama.2021.24110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.24110</ArticleId><ArticleId IdType="pmc">PMC8790664</ArticleId><ArticleId IdType="pubmed">35076665</ArticleId></ArticleIdList></Reference><Reference><Citation>Witberg G, Barda N, Hoss S, Richter I, Wiessman M, Aviv Y, et al. Myocarditis after COVID-19 vaccination in a large health care organization. N Engl J Med. 2021;385:2132&#x2013;9. doi: 10.1056/NEJMoa2110737.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2110737</ArticleId><ArticleId IdType="pmc">PMC8531986</ArticleId><ArticleId IdType="pubmed">34614329</ArticleId></ArticleIdList></Reference><Reference><Citation>Voleti N, Reddy SP, Ssentongo P. Myocarditis in SARS-CoV-2 infection vs. COVID-19 vaccination: a systematic review and meta-analysis. Front Cardiovasc Med. 2022;9:951314. doi: 10.3389/fcvm.2022.951314.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2022.951314</ArticleId><ArticleId IdType="pmc">PMC9467278</ArticleId><ArticleId IdType="pubmed">36105535</ArticleId></ArticleIdList></Reference><Reference><Citation>Patone M, Mei XW, Handunnetthi L, Dixon S, Zaccardi F, Shankar-Hari M, et al. Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection. Nat Med. 2022;28:410&#x2013;22. doi: 10.1038/s41591-021-01630-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01630-0</ArticleId><ArticleId IdType="pmc">PMC8863574</ArticleId><ArticleId IdType="pubmed">34907393</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M, Wen W, Zhou M, Wang C, Feng ZH. Meta-analysis of risk of myocarditis after messenger RNA COVID-19 vaccine. Am J Cardiol. 2022;167:155&#x2013;7. doi: 10.1016/j.amjcard.2021.12.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2021.12.007</ArticleId><ArticleId IdType="pmc">PMC8767906</ArticleId><ArticleId IdType="pubmed">35063268</ArticleId></ArticleIdList></Reference><Reference><Citation>Task Force for the Management of C-otESoC. European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1-epidemiology, pathophysiology, and diagnosis. Eur Heart J. 2022;43:1033&#x2013;58. doi: 10.1093/eurheartj/ehab696.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehab696</ArticleId><ArticleId IdType="pmc">PMC8690026</ArticleId><ArticleId IdType="pubmed">34791157</ArticleId></ArticleIdList></Reference><Reference><Citation>Bilotta C, Perrone G, Adelfio V, Spatola GF, Uzzo ML, Argo A, et al. COVID-19 vaccine-related thrombosis: a systematic review and exploratory analysis. Front Immunol. 2021;12:729251. doi: 10.3389/fimmu.2021.729251.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.729251</ArticleId><ArticleId IdType="pmc">PMC8666479</ArticleId><ArticleId IdType="pubmed">34912330</ArticleId></ArticleIdList></Reference><Reference><Citation>Scully M, Singh D, Lown R, Poles A, Solomon T, Levi M, et al. Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination. N Engl J Med. 2021;384:2202&#x2013;11. doi: 10.1056/NEJMoa2105385.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2105385</ArticleId><ArticleId IdType="pmc">PMC8112532</ArticleId><ArticleId IdType="pubmed">33861525</ArticleId></ArticleIdList></Reference><Reference><Citation>Aleem A, Nadeem AJ. Coronavirus (COVID-19) vaccine-induced immune thrombotic thrombocytopenia (VITT). In: StatPearls. Treasure Island (FL); 2022. https://www.ncbi.nlm.nih.gov/pubmed/34033367.</Citation><ArticleIdList><ArticleId IdType="pubmed">34033367</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexander GC, Tajanlangit M, Heyward J, Mansour O, Qato DM, Stafford RS. Use and content of primary care office-based vs telemedicine care visits during the COVID-19 pandemic in the US. JAMA Netw Open. 2020;3:e2021476. doi: 10.1001/jamanetworkopen.2020.21476.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2020.21476</ArticleId><ArticleId IdType="pmc">PMC7532385</ArticleId><ArticleId IdType="pubmed">33006622</ArticleId></ArticleIdList></Reference><Reference><Citation>Kario K, Nishizawa M, Hoshide S, Shimpo M, Ishibashi Y, Kunii O, et al. Development of a disaster cardiovascular prevention network. Lancet. 2011;378:1125&#x2013;7. doi: 10.1016/S0140-6736(11)61187-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(11)61187-2</ArticleId><ArticleId IdType="pubmed">21885110</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishizawa M, Hoshide S, Okawara Y, Matsuo T, Kario K. Strict blood pressure control achieved using an ICT-based home blood pressure monitoring system in a catastrophically damaged area after a disaster. J Clin Hypertens. 2017;19:26&#x2013;9. doi: 10.1111/jch.12864.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jch.12864</ArticleId><ArticleId IdType="pmc">PMC8030959</ArticleId><ArticleId IdType="pubmed">27400261</ArticleId></ArticleIdList></Reference><Reference><Citation>Omboni S, McManus RJ, Bosworth HB, Chappell LC, Green BB, Kario K, et al. Evidence and recommendations on the use of telemedicine for the management of arterial hypertension: an international expert position paper. Hypertension. 2020;76:1368&#x2013;83. doi: 10.1161/HYPERTENSIONAHA.120.15873.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.120.15873</ArticleId><ArticleId IdType="pubmed">32921195</ArticleId></ArticleIdList></Reference><Reference><Citation>Cortez C, Mansour O, Qato DM, Stafford RS, Alexander GC. Changes in short-term, long-term, and preventive care delivery in US office-based and telemedicine visits during the COVID-19 pandemic. JAMA Health Forum. 2021;2:e211529. doi: 10.1001/jamahealthforum.2021.1529.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamahealthforum.2021.1529</ArticleId><ArticleId IdType="pmc">PMC8796900</ArticleId><ArticleId IdType="pubmed">35977211</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan NA, Stergiou GS, Omboni S, Kario K, Renna N, Chapman N, et al. Virtual management of hypertension: lessons from the COVID-19 pandemic-International Society of Hypertension position paper endorsed by the World Hypertension League and European Society of Hypertension. J Hypertens. 2022;40:1435&#x2013;48. doi: 10.1097/HJH.0000000000003205.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/HJH.0000000000003205</ArticleId><ArticleId IdType="pubmed">35579481</ArticleId></ArticleIdList></Reference><Reference><Citation>Onishi Y, Ichihashi R, Yoshida Y, Tahara T, Kikuchi T, Kobori T, et al. Substitution of telemedicine for clinic visit during the COVID-19 pandemic of 2020: Comparison of telemedicine and clinic visit. J Diabetes Investig. 2022;13:1617&#x2013;25. doi: 10.1111/jdi.13826.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jdi.13826</ArticleId><ArticleId IdType="pmc">PMC9348048</ArticleId><ArticleId IdType="pubmed">35524476</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, Yuan X, Wang J, Sun C, Wang G. Telemedicine maybe an effective solution for management of chronic disease during the COVID-19 epidemic. Prim Health Care Res Dev. 2021;22:e48. doi: 10.1017/S1463423621000517.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S1463423621000517</ArticleId><ArticleId IdType="pmc">PMC8488977</ArticleId><ArticleId IdType="pubmed">34583801</ArticleId></ArticleIdList></Reference><Reference><Citation>Akiyama M, Yoo BK. A systematic review of the economic evaluation of telemedicine in Japan. J Prev Med Public Health. 2016;49:183&#x2013;96. doi: 10.3961/jpmph.16.043.</Citation><ArticleIdList><ArticleId IdType="doi">10.3961/jpmph.16.043</ArticleId><ArticleId IdType="pmc">PMC4977767</ArticleId><ArticleId IdType="pubmed">27499161</ArticleId></ArticleIdList></Reference><Reference><Citation>Nomura A, Tanigawa T, Kario K, Igarashi A. Cost-effectiveness of digital therapeutics for essential hypertension. Hypertens Res. 2022;45:1538&#x2013;48. doi: 10.1038/s41440-022-00952-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41440-022-00952-x</ArticleId><ArticleId IdType="pmc">PMC9474296</ArticleId><ArticleId IdType="pubmed">35726085</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>